Knight Therapeutics Inc. is a Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. It is listed on the Toronto Stock Exchange (symbol GUD), with a market capitalization of $1.02 billion as of August 2019.[1]
In 1995, Jonathan Ross Goodman and Mark Beaudet founded Paladin Labs, the predecessor company to Knight Therapeutics. It launched an IPO in that year at $1.50 per share.[2]
In 2011, Goodman was seriously injured in a cycling accident, forcing him to temporarily relinquish the CEO role to Mark Beaudet.[2] The accident caused serious traumatic brain injury, although Goodman has almost fully recovered.[3] Also in 2011, Paladin offered to buy Afexa Life Sciences for $57 million, but was outbid by Valeant Pharmaceuticals.[2] However, it succeeded in acquiring Labopharm for $20 million.[4]
In 2014, Endo Pharmaceuticals, an American pharmaceutical company, acquired most of the assets of Paladin Labs for $3 billion, or $151 a share, a 100 times increase from its IPO price.[5] As part of the transaction, Knight Therapeutics was spun-off to the shareholders of Paladin, with the rights to Impavido, a leishmaniasis drug.[6] It was also led by Jonathan Ross Goodman, and was in substantially the same business.
In November 2016, it was rumored that Endo was considering selling Paladin back to Knight Therapeutics, for less than it initially paid for it.[7]
Business
Knight Therapeutics, like Paladin Labs before it, focuses on marketing and licensing drugs from international drug makers for the Canada and Latin America.[3] This involves getting Health Canada approval for new products, and selling them to Canadian customers. Knight is generally not involved in initial drug discovery or development. As of June 2020, the company commercializes dozens of innovative pharmaceuticals in Canada and 10 Latin American countries with a 700+ employees.[3] Knight's main product portfolios cover Pain/Gastrointestinal, Ophthalmic, Women's Health and Oncology. Its marketed products are Movantik for the treatment of opioid-induced constipation, Probuphine, a sub-dermal implant for opioid dependence, Impavido for the treatment of leishmaniasis and Burinex for edema associated with congestive heart failure, cirrhosis of the liver and renal disease.[3]
References
^"'If Canada was efficient, I wouldn't exist:' The miraculous success of Jonathan Ross Goodman". Financial Post. 2017-07-31. Retrieved 2018-01-20.
^ abc"Paladin Labs Founder Finds a New Knight". The Montreal Gazette. 2014-04-01.
^ abcd"Goodman Rallies From Near-Death Bike Spill for Drug Renaissance". Bloomberg.com. 2017-07-31. Retrieved 2018-01-20.
^"Labopharm shareholders approve $20.5 million acquisition by Paladin Labs". Global News. Retrieved 2018-01-20.
^"It's early days for Knight Therapeutics, but chemistry is right". The Globe and Mail. 2014-09-04. Retrieved 2018-01-19.
^"Can Knight Therapeutics Inc. Repeat the Success of Paladin Labs?". The Motley Fool. 18 May 2017. Retrieved 19 January 2018.
^Reuters Editorial. "Exclusive: Endo considers sale of Paladin Labs to Knight Therapeutics". CA. Retrieved 2018-01-20. {{cite news}}: |author= has generic name (help)
External links
Official Website
February 01, 2023
knight, therapeutics, canadian, public, specialty, pharmaceutical, company, based, montreal, quebec, that, focuses, acquiring, licensing, innovative, pharmaceutical, products, canadian, select, international, markets, listed, toronto, stock, exchange, symbol, . Knight Therapeutics Inc is a Canadian public specialty pharmaceutical company based in Montreal Quebec that focuses on acquiring or in licensing innovative pharmaceutical products for the Canadian and select international markets It is listed on the Toronto Stock Exchange symbol GUD with a market capitalization of 1 02 billion as of August 2019 1 Knight Therapeutics Inc TypePublicTraded asTSX GUDS amp P TSX Composite ComponentFounded1995FounderJonathan Ross GoodmanHeadquartersMontreal Quebec CanadaKey peopleJonathan Ross Goodman Executive Chairman Samira Sakhia CEO Revenue 6 16 million 2019 Websitegud knight wbr com wbr en Contents 1 History 2 Business 3 References 4 External linksHistory EditIn 1995 Jonathan Ross Goodman and Mark Beaudet founded Paladin Labs the predecessor company to Knight Therapeutics It launched an IPO in that year at 1 50 per share 2 In 2011 Goodman was seriously injured in a cycling accident forcing him to temporarily relinquish the CEO role to Mark Beaudet 2 The accident caused serious traumatic brain injury although Goodman has almost fully recovered 3 Also in 2011 Paladin offered to buy Afexa Life Sciences for 57 million but was outbid by Valeant Pharmaceuticals 2 However it succeeded in acquiring Labopharm for 20 million 4 In 2014 Endo Pharmaceuticals an American pharmaceutical company acquired most of the assets of Paladin Labs for 3 billion or 151 a share a 100 times increase from its IPO price 5 As part of the transaction Knight Therapeutics was spun off to the shareholders of Paladin with the rights to Impavido a leishmaniasis drug 6 It was also led by Jonathan Ross Goodman and was in substantially the same business In November 2016 it was rumored that Endo was considering selling Paladin back to Knight Therapeutics for less than it initially paid for it 7 Business EditKnight Therapeutics like Paladin Labs before it focuses on marketing and licensing drugs from international drug makers for the Canada and Latin America 3 This involves getting Health Canada approval for new products and selling them to Canadian customers Knight is generally not involved in initial drug discovery or development As of June 2020 the company commercializes dozens of innovative pharmaceuticals in Canada and 10 Latin American countries with a 700 employees 3 Knight s main product portfolios cover Pain Gastrointestinal Ophthalmic Women s Health and Oncology Its marketed products are Movantik for the treatment of opioid induced constipation Probuphine a sub dermal implant for opioid dependence Impavido for the treatment of leishmaniasis and Burinex for edema associated with congestive heart failure cirrhosis of the liver and renal disease 3 References Edit If Canada was efficient I wouldn t exist The miraculous success of Jonathan Ross Goodman Financial Post 2017 07 31 Retrieved 2018 01 20 a b c Paladin Labs Founder Finds a New Knight The Montreal Gazette 2014 04 01 a b c d Goodman Rallies From Near Death Bike Spill for Drug Renaissance Bloomberg com 2017 07 31 Retrieved 2018 01 20 Labopharm shareholders approve 20 5 million acquisition by Paladin Labs Global News Retrieved 2018 01 20 It s early days for Knight Therapeutics but chemistry is right The Globe and Mail 2014 09 04 Retrieved 2018 01 19 Can Knight Therapeutics Inc Repeat the Success of Paladin Labs The Motley Fool 18 May 2017 Retrieved 19 January 2018 Reuters Editorial Exclusive Endo considers sale of Paladin Labs to Knight Therapeutics CA Retrieved 2018 01 20 a href Template Cite news html title Template Cite news cite news a author has generic name help External links EditOfficial Website Retrieved from https en wikipedia org w index php title Knight Therapeutics amp oldid 1136277552, wikipedia, wiki, book, books, library,
